BAT 7104
Alternative Names: BAT-7104Latest Information Update: 28 Jun 2025
At a glance
- Originator Bio-Thera Solutions
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Solid tumours
- No development reported Lymphoma
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-0 development in Lymphoma in China (Parenteral, Injection)
- 28 Mar 2025 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (Parenteral, Injection)
- 25 Jun 2024 Bio-Thera Solutions completes a phase-I trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (Parenteral) (NCT05200013)